血管紧张素受体阻滞剂使用与胃食管癌生存:一项基于人群的队列研究
该研究基于英格兰癌症登记处1998–2012年新诊断胃食管癌患者队列,链接处方与临床记录及死亡登记,采用时间依赖Cox回归分析诊断后血管紧张素受体阻滞剂(ARB)使用与胃食管癌特异性死亡的关系。共纳入5124例患者,其中360例使用ARB,随访期间3345例死于胃食管癌。调整混杂因素后,ARB使用者胃食管癌死亡风险较非使用者中度降低(HR=0.83,95%CI 0.71–0.98),且处方≥2年者HR最低(HR=0.42,95%CI 0.25–0.72)。作者结论为ARB使用者癌症特异性死亡中度降低,但需进一步独立流行病学研究确认并需充分分期信息。
要点
- 诊断后使用ARB与胃食管癌特异性死亡风险中度降低相关(HR=0.83,95%CI 0.71–0.98)。
- 存在剂量反应关系,处方≥2年者HR最低(HR=0.42,95%CI 0.25–0.72)。
- 作者认为需进一步独立流行病学研究确认,且需充分分期信息。
核心结论
- 在该大型基于人群的胃食管癌队列中,研究者发现ARB使用者癌症特异性死亡中度降低,但需进一步独立流行病学研究确认并需充分分期信息。
研究设计与样本
- 基于人群的队列研究,从英格兰癌症登记处选取1998–2012年新诊断胃食管癌患者,链接临床实践研究数据链的处方与临床记录及国家统计办公室死亡记录。
- 队列共纳入5124例胃食管癌患者,其中360例使用ARB,随访期间3345例死于胃食管癌。
- 采用时间依赖Cox回归模型计算风险比(HR),比较诊断后ARB使用者与非使用者的胃食管癌特异性死亡,并调整人口学特征、合并症及诊断后阿司匹林或他汀使用。
主要发现
- 调整后,ARB使用者胃食管癌死亡风险较非使用者中度降低(HR=0.83,95%CI 0.71–0.98)。
- 存在剂量反应关系的证据,接受至少2年处方者HR最低(HR=0.42,95%CI 0.25–0.72)。
局限性
- 作者结论指出需进一步独立流行病学研究确认,且需充分分期信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Angiotensin receptor blockers (ARBs; including candesartan, losartan, olmesartan and valsartan) are widely used to treat hypertension, heart failure and diabetic neuropathy. There is considerable pre-clinical evidence that ARBs can reduce cancer progression, particularly for gastric cancer. Despite this, epidemiological studies have yet to assess the impact of ARB use on gastro-oesophageal cancer survival. AIM: To investigate the association between post-diagnosis ARB use and gastro-oesophageal cancer survival. METHODS: We selected a cohort of patients with newly-diagnosed gastro-oesophageal cancer between 1998 and 2012 from English cancer registries. We linked to prescription and clinical records from the Clinical Practice Research Datalink, and to death records from the Office for National Statistics. We used time-dependant Cox-regression models to calculate hazard ratios (HRs) comparing gastro-oesophageal cancer-specific mortality between post-diagnosis ARB users and non-users, after adjusting for demographics, comorbidities and post-diagnosis aspirin or statin use. RESULTS: Our cohort included 5124 gastro-oesophageal cancer patients, of which 360 used ARBs, and 3345 died due to their gastro-oesophageal cancer during follow-up. After adjustment, ARB users had moderately lower risk of gastro-oesophageal cancer mortality than the non-users (HR = 0.83, 95% CI 0.71-0.98). There was evidence of a dose-response relationship with the lowest HRs observed among patients receiving at least 2 years of prescriptions (HR = 0.42, 95% CI 0.25-0.72). CONCLUSIONS: In this large population-based gastro-oesophageal cancer cohort, we found moderately reduced cancer-specific mortality among ARB users. However, confirmation in further independent epidemiological studies with sufficient staging information is required.
引用
- Busby J, McMenamin Ú, Spence A, et al. Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study. Aliment Pharmacol Ther. 2017. PMID: 29105106. doi:10.1111/apt.14388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。